Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PKI-179 |
Synonyms | |
Therapy Description |
PKI-179 is a dual PI3K/mTORC1/2 inhibitor that inhibits the PI3K/mTOR signaling pathway, thereby inducing apoptosis and inhibiting tumor growth (PMID: 20797855, PMID: 26500112). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PKI-179 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | PKI-179 is a dual PI3K/mTORC1/2 inhibitor that inhibits the PI3K/mTOR signaling pathway, thereby inducing apoptosis and inhibiting tumor growth (PMID: 20797855, PMID: 26500112). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mut PTEN loss | prostate cancer | sensitive | PKI-179 | Preclinical - Cell culture | Actionable | In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855). | 20797855 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|